I have to agree that Dr. Patterson is a critically
Post# of 148172
He has been instrumental in steering the company to indications, trial designs, developing/deploying methodologies for testing and proving MOA -- and he is, and will likely continue to be, the technical 'face' of the company in terms of interfacing with the FDA (and many xFDA), as well as investors and media.
We would be lost without Dr. Patterson. And, I believe it is a symbiotic relationship, as Dr. Patterson has also benefited from his association with the CytoDyn.
I hope his COVID manuscript leads to broad recognition and accolades.
Would hate to lose him in the shuffle of notoriety.